Acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Press Release | April 24, 2025 at 09:00:00 EEST |
Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies
Turku, Finland, – Faron Pharmaceuticals Ltd. (AIM: FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new Phase II data from its ongoing BEXMAB study evaluating bexmarilimab in high-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Rapid Oral Abstract Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June 2025, in Chicago, Illinois, USA.
The abstract, selected for oral communication, highlights the efficacy and tolerability of bexmarilimab, Faron’s novel humanized anti-Clever-1 antibody, with no dose-limiting toxicities during dose escalation, when used in combination with standard-of-care, azacitidine, treatment in patients with both treatment naïve (frontline) and relapsed/refractory (r/r) HR MDS patients.
"We are thrilled to see bexmarilimab’s potential continuing to translate into clinical benefit for patients with this challenging hematologic malignancy," said Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals. "The Phase II results build on our understanding of Clever-1 biology and bexmarilimab’s mode of action, and we believe this novel immunotherapy could offer a meaningful new treatment pathway for patients. The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global oncology community — ASCO "
Faron’s presence at ASCO 2025 reinforces the Company’s commitment to advancing science-driven novel immunotherapy solutions and to addressing unmet medical needs in oncology.
The details of the oral presentation are as follows:
| Session type and title | Rapid Oral Abstract – Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant | |
|---|---|---|
| Session date | 30 May 2025 | |
| Time | 1:00 PM - 2:30 PM CDT | |
| Abstract no | 6513 | |
| Presenter | Dr. Naval Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center |
About bexmarilimab
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.